This definition appears very rarely
and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other meanings of TZD
We have 5 other definitions for TZD
in our Acronym Attic
Samples in periodicals archive:
With a thiazolidinedione (TZD), adverse reactions were similar; as monotherapy, most common was nausea (8% vs 0%).
Onglyza received Marketing Authorisation in 2009 and is indicated in adult patients aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control: in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control; in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate; in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate.
to include both a DPP-4 inhibitor and a thiazolidinedione (TZD) in a single tablet.
Although a definitive link between these drugs and an increased fracture risk has not yet been proved, the evidence amassed so far is suggestive enough to prompt caution in the treatment of patients with a thiazolidinedione (TZD), Dr.
We then demonstrate that: i) RORalpha, and specifically its RORalpha1 isoform, is expressed in DU 145 cells; ii) activation of RORalpha, by means of the thiazolidinedione derivative CGP 52,608 (the synthetic RORalpha activator), significantly reduces 5-LOX expression, both at mRNA (as evaluated by comparative RT-PCR) and at protein (as investigated by Western blot analysis) level (this was confirmed by the reduced activity of 5-LOX in CGP 52,608 treated cells); and iii) the treatment of DU 145 cells with CGP 52,608 completely abrogated the proliferative action of both LA and AA.
Galvus received European Union approval in September 2007 for use in patients in combination with the anti-diabetes medicines metformin, thiazolidinedione (TZD) or a sulphonylurea (SU).
Takeda is the originator of thiazolidinedione derivatives and ACTOS is a member of the thiazolidinedione class of "insulin-sensitizing" agents, and it directly targets insulin resistance.
The group included patients who received a new prescription for either a thiazolidinedione (74,525) or insulin (67,803).